Target intelligence / Profile preview

Phosphate ion (intestinal absorption and transport) (None)

Target
None
Molecular classification
Transporter (e.g., sodium-dependent phosphate cotransporter NaPi-IIb/SLC34A2), Other (paracellular pathway/membrane transport)
01

Overview

Intestinal phosphate transport refers to the absorption of dietary inorganic phosphate ions in the small intestine via two principal mechanisms: a dominant passive paracellular pathway (~65–80% of absorption), which is poorly characterized at the molecular level, and an active transcellular pathway mediated by sodium-dependent phosphate cotransporters, primarily NaPi-IIb (SLC34A2). This process is regulated by hormones such as parathyroid hormone, FGF-23, and vitamin D, forming part of a complex gut–renal axis critical to overall phosphate homeostasis. Dysregulation of intestinal phosphate absorption contributes to hyperphosphatemia, especially in chronic kidney disease, increasing cardiovascular risk. Novel therapeutics target these pathways either by binding luminal phosphate or inhibiting relevant transporters, making intestinal phosphate absorption a clinically important target, though "gastrointestinal phosphate" itself is not a specific molecule or receptor.

Other names
Intestinal phosphate transportintestinal phosphate absorptiongut phosphate homeostasis
02

Mechanism of action

Physical binding of phosphate in the gut lumen (phosphate binders); Inhibition of paracellular absorption by altering tight junction permeability (tenapanor); Inhibition of sodium-dependent cotransport (experimental NaPi-IIb inhibitors)

03

Biological functions

Mineral absorptionMaintenance of systemic phosphate homeostasisSignal transduction (gut–renal axis)
04

Disease associations

Chronic kidney diseaseCardiovascular disease (phosphate toxicity)Vascular calcification
05

Safety considerations

Hypophosphatemia (over-suppression)Gastrointestinal side effects (e.g., diarrhea from tenapanor)Mineral/bone disorders
06

Interacting drugs

Phosphate binders (e.g., sevelamer, calcium acetate)

2 more in the full profile.

07

Biomarkers

Serum phosphate concentrationFGF-23 levelsParathyroid hormone

Beyond the preview

Go deeper on Phosphate ion (intestinal absorption and transport) (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphate ion (intestinal absorption and transport) (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call